Posted by Michael Wonder on 01 Mar 2022
Triple negative breast cancer: survival benefit with sacituzumab govitecan
1 March 2022 - Those affected survive a median of twelve months compared to seven in the control group. Overall, the Institute sees a hint of a major added benefit compared to the comparator therapy.
Sacituzumab govitecan is a new drug for the treatment of adult patients with unresectable or metastatic triple - negative breast cancer who have previously received two or more systemic therapies, including at least one for advanced disease.
